Sangamo hires Raymond James to explore strategic alternatives
Sangamo Therapeutics has retained Raymond James as financial adviser to evaluate a full range of strategic alternatives, the company announced on 8 June 2026. The Richmond, California-based genomic medicine firm said it is open to any transaction structure that advances its pipeline and maximises value for shareholders, and has invited interested parties to contact its business development team directly.
The move signals that Sangamo's board believes the company's assets are worth more in the hands of a better-capitalised partner than they would be if developed independently. The company is listed on the OTCQB Venture Market following its migration from NASDAQ, a transition that typically reflects constrained access to institutional capital.
Lead asset: Fabry gene therapy approaching BLA
The most commercially advanced programme is isaralgagene civaparvovec (ST-920), a one-time gene therapy for Fabry disease. The registrational Phase 1/2 STAAR study has completed enrolment, with 32 patients now in long-term follow-up. Sangamo said the FDA has affirmed that two-year eGFR data may serve as confirmatory evidence for traditional approval, and the company has initiated a rolling Biologics Licence Application submission under the Accelerated Approval pathway, with the first two modules already filed.
The programme carries Orphan Drug, Fast Track, and RMAT designations from the FDA, Orphan Medicinal Product designation and PRIME eligibility from the EMA, and Innovative Licensing and Access Pathway status from the MHRA — a regulatory package that meaningfully de-risks the approval timeline and may increase its attractiveness to acquirers.
Chief executive Sandy Macrae described isaralgagene civaparvovec as "best-in-class" and said the company's zinc finger epigenetic regulation, capsid delivery, and MINT large-scale genomic engineering platforms represented differentiated assets. The Biotech Times has softened these characterisations to reflect their promotional origin.
CNS pipeline and platform licensing
Beyond Fabry disease, Sangamo is running a Phase 1/2 study of ST-503, an epigenetic regulator targeting Nav1.7 for chronic neuropathic pain due to small fibre neuropathy, with seven clinical sites active. ST-506, directed at prion disease, is in Clinical Trial Application-enabling activities and has benefited from productive interactions with the MHRA on nonclinical safety and clinical study design.
Both CNS programmes rely on Sangamo's proprietary STAC-BBB AAV capsid, which the company says achieves brain-wide delivery following intravenous administration in nonhuman primates. The capsid has already been out-licensed to Genentech, Astellas, and Eli Lilly for specified neurological targets, generating $88 million in licence fees to date and up to $4.6 billion in potential future milestones and exercise fees.
Market context and competitive read-across
The strategic alternatives process places Sangamo in a crowded field of gene therapy and genomic medicine companies seeking partners or acquirers. The Fabry disease space has seen sustained interest from large pharma, with several enzyme replacement and substrate reduction therapies already approved. A one-time gene therapy with durable eGFR stabilisation data would address a meaningful unmet need for patients seeking an alternative to chronic infusion regimens, and the near-complete BLA filing reduces execution risk for any acquirer.
The CNS delivery platform may be the asset that attracts the broadest interest. Blood-brain barrier-crossing AAV capsids remain a bottleneck in neurological gene therapy, and the existing Lilly, Genentech, and Astellas licensing relationships demonstrate third-party validation at a commercial level. Sangamo has not set a timetable for the process and cautioned that no agreement has been reached and no outcome is guaranteed.